Abstracts tagged "prednisone"

Abstract Number: 1224 • 2013 ACR/ARHP Annual Meeting
Prednisone Has No Effect On Odanacatib Pharmacokinetics In Healthy Subjects
Gene Marcantonio¹, Chengcheng Liu², Stefan Zajic³, Chantal Mahon², David Hreniuk², Anish Mehta⁴, Kate Mostoller², Denise Morris⁵, Hongwei Xue⁵ and S. Aubrey Stoch², ¹Merck & Co., Whitehouse Station, NJ, ²Merck Sharp & Dohme Corp., Whitehouse Station, NJ, ³Merck Sharp & Dohme Corp, Whitehouse Station, NJ, ⁴Merck Sharp & Dohme Corp.,, Whitehouse Station, NJ, ⁵Covance, Madison, WI
Background/Purpose: We evaluated the effect of prednisone, a glucocorticoid believed to induce the CYP P450 enzyme, on the pharmacokinetics of odanacatib, a novel Cathepsin K…
Abstract Number: 799 • 2013 ACR/ARHP Annual Meeting
Clinical and Radiological Outcomes Of Two Years Remission Steered Treatment In Early Arthritis Patients
L. Heimans¹, K.V.C. Wevers-de Boer¹, G. Akdemir¹, H.K Ronday², T.H.E. Molenaar³, J. H. L. M. Van Groenendael⁴, A.J. Peeters⁵, I. Speyer⁶, G. Collee⁷, P.B. de Sonnaville⁸, B.A. Grillet⁹, T.W.J. Huizinga¹ and C.F. Allaart¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Haga Hospital, The Hague, Netherlands, ³Dept of Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁴Franciscus Hospital, Roosendaal, Netherlands, ⁵Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, ⁶Rheumatology, Bronovo Hospital, Den Haag, Netherlands, ⁷MCH, The Hague, Netherlands, ⁸Department of Rheumatology, Admiraal de Ruyter hospital, Goes, Netherlands, ⁹Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands
Background/Purpose: To evaluate outcomes after 2 years of remission steered therapy in early arthritis patients. Methods: 610 patients with early rheumatoid or undifferentiated arthritis (UA)…
Abstract Number: 2473 • 2012 ACR/ARHP Annual Meeting
A Randomized Trial in New Onset Juvenile Dermatomyositis: Prednisone Versus Prednisone Plus Cyclosporine Versus Prednisone Plus Methotrexate
Nicolino Ruperto¹, Angela Pistorio², Sheila Oliveira³, Rubén J. Cuttica⁴, Angelo Ravelli¹, Michel Fischbach⁵, Stefan Hagelberg¹, Tadej Avcin⁶, Emanuel Cheuret¹, Fabrizia Corona⁷, Gerard Couillault¹, Frank Dressler¹, Valeria Gerloni¹, Gary Sterba Sr.¹, Francesco Zulian¹, Maria Teresa Apaz¹, Adriana Cespedes-Cruz¹, Rolando Cimaz¹, Fabrizio De Benedetti⁸, Pierre Quartier¹, Ricardo Russo¹, Nico Wulffraat¹, Simona Angioloni¹ and Alberto Martini⁹, ¹Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, ²PRINTO, Genoa, Italy, ³Istituto Giannina Gaslini, Pediatria II, Reumatologia, Paediatric Rheumatology International Trials Organisation (PRINTO) Coordinating Center, Genoa, Italy, Genova, Italy, ⁴Hospital de Niños Pedro de Elizalde - University of Buenos Aires, Buenes Aires, Argentina, ⁵Pediatric Rheumatology International Trials Organization (PRINTO)-Istituto Gaslini, Genova, Italy, ⁶The Ljubljana University Medical Centre, Pediatric Clinic, Ljubljana, Slovenia, ⁷Reumatologia Pediatrica, Paediatric Department University of Milano, Milano, Italy, ⁸IRCCS Ospedale Pediatrico Bambino Gesú, Rome, Italy, ⁹Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH
Background/Purpose: Data regarding the safety and efficacy of treatment regimens for juvenile dermatomyositis(JDM) tends to be from anecdotal, small, uncontrolled, non-randomized case series. This randomized…
Abstract Number: 2376 • 2012 ACR/ARHP Annual Meeting
Behcet’s Disease: Combination of Pulse Cyclophosphamide, Azathioprine, and Prednisolone for the Treatment of Retinal Vasculitis; Longitudinal Study On 10 Years
Fereydoun Davatchi¹, Farhad Shahram², Bahar Sadeghi Abdollahi², Hormoz Shams², Abdolhadi Nadji², Massoomeh Akhlaghi², Tahereh Faezi² and Farimah Ashofteh², ¹Rheumatology Research Ctr and Department of Rheumatology, Shariati Hospital-Tehran Univ, Tehran, Iran, ²Rheumatology, Behcet's Unit, Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran
Background/Purpose: Ocular lesions of Behcet’s Disease (BD), need aggressive treatment to prevent severe loss of vision or blindness. Cytotoxic drugs are the main therapeutic agents…
Abstract Number: 2356 • 2012 ACR/ARHP Annual Meeting
Visual Manifestations in Giant Cell Arteritis : Trend Over Five Decades
Abha G. Singh¹, Cynthia S. Crowson², Tanaz A. Kermani³, Cornelia M. Weyand⁴, Eric L. Matteson¹ and Kenneth J. Warrington⁵, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³Rheumatology, University of California Los Angeles, Los Angeles, CA, ⁴Medicine, Stanford University School of Medicine, Stanford, CA, ⁵Division of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Cranial ischemic complications, particularly permanent visual loss, are catastrophic complications of giant cell arteritis (GCA). Corticosteroids have been used to decrease the risk of…
Abstract Number: 2120 • 2012 ACR/ARHP Annual Meeting
Predictive Value of Anti-CCP Positivity On Disease Course and Response to Therapy in Early Rheumatoid Arthritis. Results From the Swedish EIRA Study
Saedis Saevarsdottir¹, Marie Holmqvist², Johan Askling³, Lars Alfredsson⁴ and Lars Klareskog⁵, ¹Rheumatology Unit, Dept. of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Department of Medicine, Rheumatology Unit & Clinical Epidemiology Unit, Karolinska Institute, Stockholm, Sweden, ⁴Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁵Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Does anti-CCP-positivity predict disease course and response to therapy in early rheumatoid arthritis (RA)? Methods: We retrieved clinical follow-up data for patients entering the…
Abstract Number: 1696 • 2012 ACR/ARHP Annual Meeting
Quantitative Evaluation of Dermal Atrophy by High-Resolution Ultrasonography, Comparing Between Patients Under Long-Term Treatment with Prednisolone or Methylprednisolone
Tim Pottel¹, Christoph Schäfer² and Gernot Keyßer², ¹Universitätsklinikum Kröllwitz, Department of Internal Medicine II, 06114 Halle (Saale), Germany, ²Universitätsklinikum Kröllwitz, Department of Internal Medicine II, 06120 Halle (Saale), Germany
Background/Purpose: The katabolic effects of a systemic treatment with glucocorticoids can lead to a progressive atrophy of the skin. Clinical observation suggests a more pronounced…
Abstract Number: 1228 • 2012 ACR/ARHP Annual Meeting
Contributions of Inflammation, Inactivity, and Low Dose Prednisone Use to Skeletal Muscle Insulin Resistance in Well-Controlled Rheumatoid Arthritis
Hiba Abouassi, Lori Bateman, Gary E. McDaniel, Lorraine Elliott-Penry, Michael Muehlbauer, E. William St. Clair, William E. Kraus and Kim M. Huffman, Medicine, Duke University Medical Center, Durham, NC
Background/Purpose: Rheumatoid arthritis (RA) is associated with a high prevalence of insulin resistance. Most prior investigations of insulin resistance in RA have examined fasting glucose…
Abstract Number: 684 • 2012 ACR/ARHP Annual Meeting
Correlation of Signal Transducers and Activators of Transcription-1 and Microrna-146a with Anaemia and Other Clinical Features in Systemic Lupus Erythematosus Patients
Paul R. Dominguez-Gutierrez¹, Angela Ceribelli¹, Minoru Satoh², Eric S. Sobel³, Yi Li², Westley H. Reeves⁴ and Edward K.L. Chan¹, ¹Oral Biology, University of Florida, Gainesville, FL, ²Medicine, University of Florida, Gainesville, FL, ³Medicine/Div of Rheumatology, University of Florida, Gainesville, FL, ⁴Rheumatology & Clinical Imm, University of Florida, Gainesville, FL
Background/Purpose: Anaemia is one of the most common haematological manifestations in SLE patients, occurring in about 50% of active cases. STAT1 is a critical signalling…
Abstract Number: 353 • 2012 ACR/ARHP Annual Meeting
The Effect of Combination Therapy and Prednisolone On Haemostatic Markers in Rheumatoid Arthritis
Inge A.M. van den Oever¹, Danka J.F. Stuijver², Debby den Uyl³, Bregje van Zaane⁴, Marieke M. ter Wee⁵, Willem F. Lems⁵, Dirkjan van Schaardenburg¹, Joost C.M. Meijers⁴, Victor E.A. Gerdes⁴ and M. T. Nurmohamed⁶, ¹Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Vascular Medicine, Academic Medical Center, Amsterdam, Netherlands, ³Rheumatology, VU University medical centre, Amsterdam, Netherlands, ⁴Internal Medicine, Slotervaart Hospital, Amsterdam, Netherlands, ⁵Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁶VU University Medical Center/Jan van Bremen Research Institute, Amsterdam, Netherlands
Background/Purpose: There is accumulating evidence that rheumatoid arthritis (RA) should be considered as prothrombotic state, explaining the increased risk of thromboembolic events. Suppressing inflammation could…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].